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Received April 25, 2012; accepted June 18, 2012AbstractBackground: Malignant gastric outlet obstruction (MGOO), a late complication of advanced carcinoma of the stomach, duodenum, periampulla
or pancreas, causes significant malnutrition and morbidity. The current treatment for MGOO is palliative in nature, with the goal of maintaining
the best quality of life possible during the terminal phase of the illness.
Methods: A total of 38 patients with MGOO were enrolled in our institute from January 2007 to December 2011; 18 patients received naso-
jejunal (NJ) feeding tube placement, and 20 patients received duodenal stent placement. Food intake, measured by the gastric outlet obstruction
scoring system (GOOSS), survival, complications, recurrent obstructive symptoms, and reintervention were evaluated in both groups.
Results: No significant differences were noted with regard to patient characteristics, survival rate (NJ group: 140 days vs. stent group: 186 days,
p ¼ 0.617), and complication rate. Recurrent obstructions developed more frequently in patients treated with NJ feeding tube placement than in
those treated with duodenal stent placement [12 (66.7%) vs. 5 (25%), p ¼ 0.014]. The duration for patency was shorter in the NJ group than in
the stent group (median: 40 days vs. 130 days, p ¼ 0.009). The GOOSS score was significantly better in the stent group than in the NJ group.
Conclusion: NJ tube placement and duodenal stent placement are both effective and safe treatments for patients with MGOO. Both groups had
similar complication rates and survival rates. While NJ tube placement is associated with lower costs, stent placement has a longer duration of
patency, superior oral intake, and a lower reintervention rate. We suggest that stent placement should be considered first in patients who are able
to afford the related costs.
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http://dx.doi.org/10.1016/j.jcma.2012.08.013duodenum, periampulla or pancreas, typically results in
significant malnutrition and morbidity.1e3 The majority of
patients with MGOO are in a preterminal stage, and have short
life expectancies.1 Symptoms of MGOO include persistent
severe nausea and vomiting, poor oral intake, and body weight
loss,2 which customarily lead to dehydration, malnutrition,
cachexia, and poor quality of life.4 When dealing with this
type of situation, possible palliative chemotherapy and radio-
therapy cannot be administered due to generalized cachexia.hinese Medical Association. All rights reserved.
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surgical gastrojejunostomy (GJ) and stent placement.3 GJ
has better long-term outcomes, although stent placement has
superior short-term outcomes.4 In contrast, however, GJ has
a higher mortality rate, morbidity risk, prolonged hospital stay,
and delayed symptom relief as compared with metallic stents,
and stent placement has a higher occlusion rate.4 In consid-
eration of generalized cachexia, advanced age, or multiple
comorbidities, it would appear that stent placement is the only
palliative option to be considered for patients with MGOO.
However, metallic stents are so expensive that many
patients cannot afford to use them, and in such cases tube
feeding can be considered. The cost of a nasojejunal (NJ)
tube is cheaper than that of a metallic stent. Patients with
cerebrovascular accident, perioperative status, burns, sepsis,
pancreatitis, gastrointestinal tract cancer or surgery, and
miscellaneous illnesses are generally considered for NJ tube
feeding.5 If obstruction of the NJ tube occurs, tube replace-
ment can easily be performed. The aim of this study was to
compare the clinical outcomes of NJ tube placement with stent
placement in patients with MGOO.
2. Methods2.1. PatientsA total of 38 patients with inoperable malignant carcinoma
causing MGOO were retrospectively reviewed at the Taipei
Veterans General Hospital from January 2007 to December
2011. Initially, MGOO was confirmed by endoscopy or
radiological studies. Exclusion criteria included prior patient
subtotal or total gastrectomy, or complete obstruction of the
gastric outlet. However, it should be noted that all the patients
had obstructive symptoms, such as nausea, vomiting, and poor
oral intake. This study was approved by the Institutional
Review Board of the Taipei Veterans General Hospital (No.
2012-01-002AC).2.2. Procedure for NJ tube placementThe NJ tube (Freka Trelumina, CH/Fr 16/9, 150 cm; Fre-
senius Kabi Ltd, Runcorn, UK) was inserted under fluoro-
scopic guidance. A 5-Fr modified pigtail catheter and guide
wire (0.035 in, 260 cm; Terumo, Tokyo, Japan) were intro-
duced into the stomach, and passed through the pylorus to the
duodenum. Water-soluble radiographic contrast was injected
to map the route of duodenum and jejunum after which the
wire was advanced into the proximal jejunum. Thereafter, an
NJ tube was introduced with the support of another stiff Ter-
umo guide wire. Finally, the tube was pushed to the proximal
jejunum about 10 cm below the ligament of Treitz.2.3. Procedure for stent placementAll stents were deployed using a standard gastroscope (JF-
240/260; Olympus, Japan) under fluoroscopic guidance. A
guide wire (0.035 in, 460 cm, Hydra Jagwire; BostonScientific Corporation, Natick, MA, USA) was introduced
through the working channel of the endoscope to 20 cm
beyond the site of obstruction. Water-soluble radiographic
contrast was injected to determine the length and location of
the stricture. The stent was chosen by the length of an addi-
tional 1e3 cm on either side of the stricture. The uncovered
stent (WallFlex duodenal stent; Boston Scientific Corporation,
Natick, MA, USA) was deployed under fluoroscopic guidance.
One day later, radiological follow-up was undertaken to
evaluate the expansion and location of the inserted metallic
stent.2.4. Evaluation of gastric outlet obstruction scoring
systemThe primary outcome of the study was the improvement of
food intake. It was measured by the gastric outlet obstruction
scoring system (GOOSS) score, with 0 ¼ no oral intake,
1 ¼ liquid diet, 2 ¼ soft diet, and 3 ¼ regular diet.2 Based on
these data, clinical success was defined as relief of obstructive
symptoms and improvement of oral intake. Other outcomes
including technical success, complications, persistent and
recurrent obstructive symptoms, reinterventions, and survival
were also evaluated.
Technical success of the NJ tube or stent placement was
defined as adequate deployment and positioning of the NJ tube
or stent with improved food intake. Both minor and major
complications were included. Minor complications were
defined as those that were not life-threatening conditions and
did not require further aggressive treatment, such as abdom-
inal pain, nausea, and vomiting. Major complications were
defined as life-threatening or severe complications, such as
aspiration pneumonia, bleeding, perforation, stent migration,
and sepsis. Reobstruction was defined as obstructive symp-
toms developing after treatment, such as persistent severe
nausea, vomiting, and poor oral intake. The dysfunction or
dislocation of NJ tube was also considered reobstruction.
Reintervention was defined as repeated treatment for recurrent
obstruction.2.5. Data collectionData were obtained from patient notes, radiology reports,
procedure notes, and telephone interviews. The collected data
included patient demographics, procedural characteristics,
complications, GOOSS score, duration of tube or stent
patency, reinterventions, and survival rate.2.6. Statistical analysisThe demographics, GOOSS score, complications, recurrent
obstructions, reintervention, time to reintervention, and 30-day
mortality were calculated using the ManneWhitney U test,
Chi-square test, or Fisher exact probability test as was
appropriate. Survival curves and incidence of recurrence were
analyzed by KaplaneMeier analysis. A p value <0.05
was considered to be statistically significant. All statistical
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Social Sciences (SPSS version 17.0 for Windows; SPSS Inc.,
Chicago, IL, USA).
3. Results3.1. Patient characteristicsThe study included 38 patients of which 18 received NJ
feeding replacement (mean age: 71  16 years, range 36e92
years) and 20 underwent duodenal stent placement (mean age:
70  18 years, range 31e94 years). There were no significant
differences between these two groups with regard to age,
gender, tumor stage, tumor origin, tumor pathology, perfor-
mance status, GOOSS score, obstructive location, body mass
index, and administration of prior adjuvant radiotherapy,
chemotherapy or both (Table 1). Most of our patients suffered
from terminal gastric adenocarcinoma; therefore, we further
compared major subgroups between the NJ and stent groups.
However, even after additional comparison, no significantTable 1
Comparison of the demographic data of NJ feeding tube placement and stent
placement.
Parameter NJ tube (n ¼ 18) Stent (n ¼ 20) p
Age (y/o) 70.7  16.0 69.6  18.4 0.836
Gender (M:F) (%) 11/7 (61.1/38.9) 13/7 (65/35) 0.804
BMI 18.5  2.69 19.6  2.47 0.262
Performance status (%) 0.375
0 0 3 (15)
1 1 (5.6) 3 (15)
2 2 (11.1) 2 (10)
3 10 (55.6) 8 (40)
4 5 (27.7) 4 (20)
Tumor origin (%) 0.476
Stomach 11 (61.1) 16 (80)
Duodenum 1 (5.6) 0
Pancreas 2 (11.1) 2 (10)
Metastatic tumor 4 (22.2) 2 (10)
Tumor stage (%) 0.499
I 0 0
IIA 1 (5.6) 0
IIB 1 (5.6) 0
IIIA 1 (5.6) 1 (5)
IIIB 0 0
IV 15 (83.2) 19 (95)
Pathology of cancer (%) 0.495
Adenocarcinoma 14 (77.7) 17 (85)
Metastatic cancer 0 1 (5)
Poorly differentiated
carcinoma
1 (5.6) 0
Unknown 3 (16.7) 2 (10)
Site of obstruction (%) 0.531
Antrum 5 (27.7) 9 (45)
Pylorus 7 (39) 8 (40)
Bulb of duodenum 1 (5.6) 0
Second portion of
duodenum
5 (27.7) 3 (15)
Prior radiation and/or
chemotherapy (%)
9 (50) 11 (55) 0.418
BMI ¼ body mass index; GOOSS ¼ gastric outlet obstruction scoring system;
NJ ¼ nasojejunal; SD ¼ standard deviation. All data were expressed as
mean  SD.differences in tumor origin, tumor stage, and pathology were
noted.3.2. Technique successThe NJ feeding tubes and duodenal stents were successfully
deployed in all the patients.3.3. Clinical successImprovement in oral intake was observed in both groups
(Table 2). Information about food intake during the 30-day
follow-up was obtained from 8/18 (44%) patients after NJ
feeding tube placement, and from 18/20 (90%) patients after
duodenal stent placement (Table 2). The GOOSS scores were
significantly different between the NJ and stent groups on 1-day,
7-day, and 30-day follow-ups, respectively. It was observed that
the patients treated with stent placement had better GOOSS
scores than those treated with an NJ tube (Table 2).3.4. Complications and reinterventionsMinor complications were noted after 1-week follow-up in
six patients in the NJ group and seven patients in the stent
group. The most common minor complications after NJ
feeding tube placement were abdominal pain, vomiting, and
diarrhea. The same symptoms, except for diarrhea, were also
noted in the stent group. Aspiration pneumonia was detected
in both groups and stent migration developed in one patient
after duodenal stent placement. However, there were no
differences between these two groups as regards to minor and
major complications (Table 3).Table 2
Comparison of oral intake.
Parameter NJ tube (n ¼ 18) Stent (n ¼ 20) p
GOOSS score before
treatment (%)
0.087
0 18 (100) 17 (85)
1 0 3 (15)
2 0 0
3 0 0
24-h GOOSS 0.016*
0 1 0
1 17 13
2 0 6
3 0 1
1-week GOOSS <0.001*
0 1 0
1 14 1
2 0 12
3 0 6
30-day GOOSS <0.001*
0 1 0
1 7 1
2 0 10
3 0 7
*p < 0.05.
GOOSS ¼ gastric outlet obstruction scoring system; NJ ¼ nasojejunal.
Table 3
Complications related to the procedures.
Parameter NJ tube (n ¼ 18) Stent (n ¼ 20) p
Minor complications (%) 0.396
None 12 (66.6) 13 (65)
Abdominal pain 1 (5.6) 2 (10)
Nausea 0 2 (10)
Vomiting 3 (16.7) 3 (15)
Diarrhea 2 (11.1) 0
Major complications (%) 0.112
None 15 (83.3) 19 (95)
Aspiration pneumonia 3 (16.7) 0
Stent migration 0 1 (5)
NJ ¼ nasojejunal.
627C.-L. Lin et al. / Journal of the Chinese Medical Association 75 (2012) 624e629A total of 17 patients had obstructive episodes after NJ tube
or stent placement was performed, but only 14 patients
received further intervention. The remaining three patients
were provided hospice care because they were at a terminal
stage of cancer. Recurrent obstructions developed more
frequently in the NJ group than in the stent group (Fig. 1). In
the NJ group, 12 recurrent episodes were noted after NJ tube
placement, of which 11 patients underwent reintervention:
6 patients received NJ tube placement, 4 patients received
stent placement, and 1 patient underwent jejunostomy. In
the stent group, a total of five recurrent episodes were noted
after stent placement, but only three underwent reintervention.
One stent migrated to the third portion of duodenum 38 days
after stent placement, which was subsequently removed via
endoscope. Another two episodes of stent obstruction occurred
due to tumor ingrowth; one patient received a new stent
placement, and the other patient received argon plasma
coagulation ablation.
The duration for patency was shorter in the NJ group as
compared with the stent group (median: 40 days vs. 130 days,
p ¼ 0.009). The time to reintervention was modestly shorter inFig. 1. The incidence of recurrent obstructions censored for patients with
malignant gastric outlet obstruction who are still alive after treatment with
either nasojejunal (NJ) feeding tube placement or stent placement in patients.the NJ group than in the stent group (median: 44 days vs.
96 days, p ¼ 0.266) (Fig. 2).3.5. SurvivalThe 30-day mortality rate was not different between these
two groups (16.7% vs. 20%, p ¼ 1.000). There were similar
median survivals in both groups (140 days vs. 186 days,
p ¼ 0.617) (Fig. 3).4. Discussion
In this retrospective study, we compared NJ tube placement
with stent placement, and further evaluated whether NJ tube
placement could be used as an alternative method to replace
stent placement in patients with MGOO. There are some
limitations in performing both procedures, such as facial and
cranial injuries, anatomic difficulties, the inability to pass
a guide wire through the stricture, multiple intestinal strictures
or obstructions, and recent gastrointestinal surgery with fresh
sutures.6e8
Complications related to both procedures may affect the
severity of the underlying disease and are also associated with
a longer hospital stay.4 Minor complications, such as abdom-
inal pain and vomiting, may develop after performing both
procedures. Intractable nausea and vomiting are common in
patients with MGOO,9 and having an uncomfortable sensation
over the pharyngeal region is common after NJ tube place-
ment. However, this could lead to further vomiting and NJ
tube dislocation. In our study, one patient developed NJ tube
dislocation 1 day after his procedure due to severe vomiting. In
contrast, these minor complications did not damage the
effectiveness of the metallic stent. Diarrhea is a common
complication of enteral feeding, and its etiology may be
a multifactorial process, such as concurrent use of antibiotics,
altered bacterial flora, formula composition, method of infu-
sion, hypoalbuminemia, and diet contamination.10 TheFig. 2. Time to reintervention after treatment with either nasojejunal (NJ)
feeding tube placement or stent placement in patients with malignant gastric
outlet obstruction.
Fig. 3. Overall survival curves after treatment with either nasojejunal (NJ)
feeding tube placement or stent placement in patients with malignant gastric
outlet obstruction.
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2.3% to 68%,11,12 and it was 11.1% in our NJ group.
The major complication rates were similar in both of our
groups, especially with regard to aspiration pneumonia. The
development of aspiration pneumonia after tube feeding has
been reported to range from 2% to 95%,11,13 and the rate in
our study was 22.2%. Aspiration of diet can develop without
any obvious vomiting, particularly in those patients with poor
mental or performance status.5 Regurgitation is usually silent
until vital signs are compromised or pneumonia develops.5
Our patients in later stages of the disease with generalized
cachexia are particularly at risk of developing aspiration
pneumonia. Other severe complications, such as bleeding or
perforation, did not occur in either of our groups.
The manufacturer of the NJ tube (Fresenius Kabi Ltd, UK)
suggests that the duration of tube use can be up to 6 weeks,
and the American Gastroenterological Association in 1995
also recommended tube feeding for short-term (<30 days)
nutritional support.10 In our study, the mean duration of NJ
tube use was 40 days, and the maximal duration was 191 days.
Therefore, an NJ tube could be used until dysfunction occurs.
The causes of NJ tube dysfunction in our study were food- or
drug-related clogging, unintentional tube removal, and tube
dislocation. Ciocon et al reported in a prospective study that
events of agitation and self-extubation after tube feeding were
67% and 39%, respectively.14 The occurrence of unintentional
tube removal was 11.1% in our study. Therefore, stent place-
ment should be considered in those patients with agitation and
self-extubation.
The common causes of reintervention after stent placement
are tumor overgrowth or ingrowth, stent migration, food
impaction, and biliary obstruction.8 Laasch et al reported that
20e25% of patients after stent placement needed endoscopic
reintervention,15 and this figure was 25% in our series. In our
study, stent migration usually resulted from the decrease ofobstruction after chemotherapy. According to a prospective
study,16 chemotherapy and radiation therapy would likely
decrease tumor burden and slow the rate of tumor growth.
Thus, such palliative treatment could further prolong stent
patency.
Although our stent for MGOO was uncovered to prevent
migration and could be obstructed by tumor ingrowths under
a longer period of observation, the interval of recurrent
obstructive symptoms was shorter in the NJ group than that
observed in the stent group. The smaller and longer lumen of
the NJ tube as compared with the metallic stent could be the
primary reason for this difference.
The patients after NJ placement could only be fed with
an NJ formula diet (GOOSS ¼ 1), but patients after
stent placement could eat a liquid diet or regular diet
(GOOSS ¼ 1e3) depending on the clinical status of the
patient. Therefore, the GOOSS score in the stent group was
better than in the NJ group, and there was a significant
difference at 24-hour, 1-week, and 30-day intervals. In addi-
tion, long-term results with regard to recurrent obstructive
symptoms were better after stent placement than after NJ tube
placement. However, despite adequate nutrition, the long-term
prognosis of both groups was still poor because of the
underlying disease.
Median survival after NJ tube placement in this study was
140 days, and no previous related data were available in the
current literature. Median survival after stent placement in our
study was 186 days, as compared with other studies that
ranged from 7 to 152 days.8,16e23 Jemal et al reported that
patients with a primary pancreatic carcinoma had a shorter
survival duration than those with a gastric or duodenal carci-
noma.24 The median survival period in our patients was
slightly longer than in other studies, and this could be the
reason that most of our patients had gastric carcinoma. No
previous studies were available regarding the difference of
survival rates in both groups. In our study, there was no
significant difference in survival rates between the two groups;
this might result from no definite treatment about the malig-
nancy itself at a poor performance status stage. In addition, no
difference in outcomes between gastric carcinoma and non-
gastric carcinoma subgroups was found (data not shown in the
result).
Fees related to NJ tube or metallic stent in MGOO are not
covered by the Bureau of National Health Insurance in
Taiwan. The prices of an NJ tube and metallic stent are around
US$100 and US$2300, respectively, in Taiwan. Therefore, the
patients with a lower economic status may choose NJ tube
placement to improve their nutrition. Although a higher
dysfunction rate is associated with NJ tube, the use of NJ tube
could still provide nutrition and achieve a similar survival rate
as compared with that of the metallic stent.
Despite the limitations of this retrospective study, our
study suggests that NJ tube placement and duodenal stent
placement are both effective and safe treatment methods for
patients with MGOO. Both groups had similar complication
rates and survival rates. While NJ tube placement is associ-
ated with lower costs, stent placement has a longer duration
629C.-L. Lin et al. / Journal of the Chinese Medical Association 75 (2012) 624e629of patency, a better oral intake, and a lower reintervention
rate. We suggest that stent placement should be considered
first in patients who are able to afford the related costs.
Further large and randomized controlled trials are needed to
compare the quality of life and survival after NJ tube
placement with that of metallic stent placement in patients
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